"IPO New Year" capital continues to contribute to innovative research and development 2020 Bio-industry listing summary

2020, has quietly passed, has not yet returned to God? In 2020, the outbreak of the new crown epidemic accelerated the pace of development of the entire biological industry, in the face of challenges at the same time ushered in new development opportunities, diagnostic and vaccine industry attention continued to increase, the industry ushered in a new golden period of development, the new drug research and development field reshuffle accelerated, capital to more innovative value of enterprises gathered.
According to incomplete statistics, a total of 72 IPOs in China's biopharmaceutical sector will raise more than 260 IPOs in 2020, including 45 A-share listed companies, 23 Hong Kong-listed companies and 4 NASDAQ-listed companies.
is noteworthy that 59 of the 72 IPOs have chosen to list on the Corst Board (37) and the Hong Kong Stock Exchange (22).
it is not difficult to see that the Hong Kong Stock Exchange and the Kotson board are still relatively hot listing places.
of listed companies, most have not yet made a profit, thanks to policy support and capital-driven, more listed companies gradually increased.
Medicine and biotechnology with the acceleration of the industry reshuffle, traditional pharmaceutical enterprises gradually to innovative pharmaceutical research and development enterprises, to domestic cancer innovation drug research and development head enterprise Hengrui Pharmaceutical, for example, its research and development investment is also the highest of its kind in state-owned enterprises.
spending on research and development in the first half of 2019 totaled 1,484 million yuan.
According to the xu Jiaxuan team statistics of CITIC Securities, in all the A-H shares, the top 100 were selected by the order of how much research and development expenditure, the total research and development expenditure was 24.9 billion yuan, accounting for 84% of all listed pharmaceutical companies.
than in the same period last year, the average increase was more than 19%.
investment in research and development, the need for corporate financing to go public has become urgent.
long cycle and high investment in research and development, prompting companies to opt for longer-term capital injections through IPOs.
in addition, as some of the companies with popular targets in the layout enter the commercial competition stage, the future of innovative drug research and development must be truly innovative, need to be Best-in-class or First-in-class.
, compared with the hot target, enterprises around a certain segment of professional areas with certain technical barriers will be the attention and favor of investment institutions.
diagnostic and genetic testing according to incomplete statistics, in 2020 the field of diagnosis and genetic testing listed enterprises a total of 13, of which 7 are listed on the main board of the Shanghai Stock Exchange, 2 are listed on the main board of the Shanghai Stock Exchange, 2 are listed on the Shenzhen Stock Exchange, 1 is on the Hong Kong Stock Exchange and 1 is on the NASDAQ.
in the field of diagnosis and genetic testing enterprises listed to choose the majority of the board, data show that the board's preference for IVD enterprises concentrated in POCT, chemical luminescence, PCR molecular diagnosis and other fields, declared enterprises characterized by average income of more than 200 million yuan, net profit of more than 40 million yuan of large-scale enterprises.
the beginning of the opening gong, the medical and health sector declaration enterprises to profit-oriented medical device enterprises, of which IVD enterprises benefit first, accounting for nearly 25%, science and technology board to unlisted IVD enterprises to provide a more convenient and efficient IPO path and higher market valuation.
medical device statistics show that in 2020, there will be 10 IPOs in the medical device sector, 7 on the Science and Technology Board, 2 on the Hong Kong Stock Exchange and 1 on the Shenzhen Stock Exchange.
Among the medical device companies listed this year, interventional device developer Peijia Medical, orthopaedic implant equipment developer Sanyou Medical, etc. have all followed the domestic alternative route, and Peijia Medical's public offering has been oversubscribed nearly 1200 times, with a frozen capital of more than 260 billion yuan, earning the new stock "King of Gold Absorption";
medical devices start later than foreign enterprises, there is a certain market space for import substitution.
as the gap between domestic and foreign countries narrows, so will the space for import substitution.
Xiaoqin, a partner at Star Capital, said in a media interview: "Medical devices, in the import substitution, grass-roots volume and other logic, medical devices have become the investment highlights of this year."
The overall development path of medical devices is very much like innovative drugs, will also go through the process from import substitution to independent innovation, the current public hospitals are basically using foreign medical devices, it is not difficult to see how much market share of medical devices will be next.
, medical devices are also evolving toward miniaturization, intelligence, and digitalization, with the emergence of minimally invascopic surgical instruments and devices with AI visual recognition capabilities.
" medical services, vaccines, CRO statistics show that in 2020, JD.com Health and Haijia Medical are listed on the Hong Kong Stock Exchange, two vaccine companies, Consino and Pre-Science Bio, are listed on the Science and Technology Board, and CRO Tiger Pharmaceuticals is listed on the Hong Kong Stock Exchange.
, JD.com Health is China's largest online healthcare platform and the second-largest IPO in the Hong Kong stock market in 2020.
, with the global pandemic of neo-crown pneumonia, the focus on heat is gradually increasing.
awareness of vaccinations has also increased, with a rapid capital response and increased attention to the vaccine market.
although the domestic vaccine industry in inactivation, detoxification and other traditional technology platform and foreign small gap, but in nucleic acid and other new technology platform is still in its infancy.
to the development of the new crown vaccine as an example, the domestic inactivation, detoxification technology routes, foreign mRNA, DNA nucleic acid technology routes.
the above contents of the data source from the network, if there are errors or omissions, please take the official published data.
。